Determination of time-dependent inactivation of CYP3A4 in cryopreserved human hepatocytes and assessment of human drug-drug interactions

Drug Metabolism and Disposition

Volumn 39, Issue 11, 2011, Pages 2085-2092

  Chen, Yuan ^a   Liu, Liling ^a,b   Monshouwer, Mario ^a,c   Fretland, Adrian J ^a  

^a ROCHE BIOSCIENCE   (United States)

^b HOFFMANN LA ROCHE INC   (United States)

^c JOHNSON AND JOHNSON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPRAZOLAM; CYCLOSPORIN; CYTOCHROME P450 3A4; DILTIAZEM; ERYTHROMYCIN; METOPROLOL; MIDAZOLAM; NIFEDIPINE; SILDENAFIL; SIMVASTATIN; THEOPHYLLINE; TRIAZOLAM; TROLEANDOMYCIN; VERAPAMIL;

ARTICLE; CONTROLLED STUDY; CRYOPRESERVATION; DRUG INTERACTION; DRUG POTENCY; DRUG PROTEIN BINDING; ENZYME INHIBITION; HUMAN; HUMAN CELL; INHIBITION KINETICS; LIVER CELL; LIVER MICROSOME; PHARMACOLOGICAL PARAMETERS; PRIORITY JOURNAL; SIMULATION; TIME DEPENDENT INHIBITION;

CRYOPRESERVATION; CYTOCHROME P-450 CYP3A; DILTIAZEM; DRUG INTERACTIONS; ENZYME ACTIVATION; ENZYME INHIBITORS; ERYTHROMYCIN; HEPATOCYTES; HUMANS; MICROSOMES, LIVER; PHARMACOKINETICS; RISK ASSESSMENT; TIME FACTORS; TROLEANDOMYCIN; VERAPAMIL;

EID: 80054733298     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.111.040634     Document Type: Article

References (21)

1. Galetin A, Burt H, Gibbons L, and Houston JB (2006) Prediction of time-dependent CYP3A4 drug-drug interactions: impact of enzyme degradation, parallel elimination pathways, and intestinal inhibition. Drug Metab Dispos 34:166-175. (Pubitemid 43042658)
2. Ghanbari F, Rowland-Yeo K, Bloomer JC, Clarke SE, Lennard MS, Tucker GT, and Rostami- Hodjegan A (2006) A critical evaluation of the experimental design of studies of mechanism based enzyme inhibition, with implications for in vitro-in vivo extrapolation. Curr Drug Metab 7:315-334.
3. Grimm SW, Einolf HJ, Hall SD, He K, Lim HK, Ling KH, Lu C, Nomeir AA, Seibert E, Skordos KW, et al. (2009) The conduct of in vitro studies to address time-dependent inhibition of drug-metabolizing enzymes: a perspective of the pharmaceutical research and manufacturers of America. Drug Metab Dispos 37:1355-1370.
4. Ito K, Ogihara K, Kanamitsu S, and Itoh T (2003) Prediction of the in vivo interaction between midazolam and macrolides based on in vitro studies using human liver microsomes. Drug Metab Dispos 31:945-954. (Pubitemid 36759066)
5. Jamei M, Marciniak S, Feng K, Barnett A, Tucker G, and Rostami-Hodjegan A (2009) The Simcyp population-based ADME simulator. Expert Opin Drug Metab Toxicol 5:211-223.
6. Jouin D, Blanchard N, Alexandre E, Delobel F, David-Pierson P, Lavé T, Jaeck D, Richert L, and Coassolo P (2006) Cryopreserved human hepatocytes in suspension are a convenient high throughput tool for the prediction of metabolic clearance. Eur J Pharm Biopharm 63:347-355. (Pubitemid 43792440)
7. Kirby BJ, Collier AC, Kharasch ED, Whittington D, Thummel KE, and Unadkat JD (2011) Complex drug interactions of HIV protease inhibitors 1: inactivation, induction and inhibition of cytochrome P450 3A by ritonavir or nelfinavir. Drug Metab Dispos 39:1070-1078.
8. Lukacova V, Chung JI, Woltosz WS, Bolger MB. Physiologically-based pharmacokinetic (PBPK) models for prediction of time-dependent enzyme inhibition (TDI): effect of diltiazem on midazolam and quinidine. Poster presented at the American Association of Pharmaceutical Scientists Annual Meeting and Exposition; 2010 Nov 14-18; New Orleans, LA. American Association of Pharmaceutical Scientists, Arlington, VA.
9. Mayhew BS, Jones DR, and Hall SD (2000) An in vitro model for predicting in vivo inhibition of cytochrome P450 3A4 by metabolic intermediate complex formation. Drug Metab Dispos 28:1031-1037. (Pubitemid 30660356)
10. McGinnity DF, Berry AJ, Kenny JR, Grime K, and Riley RJ (2006) Evaluation of timedependent cytochrome P450 inhibition using cultured human hepatocytes. Drug Metab Dispos 34:1291-1300. (Pubitemid 44079869)
11. Obach RS, Walsky RL, and Venkatakrishnan K (2007) Mechanism-based inactivation of human cytochrome P450 enzymes and the prediction of drug-drug interactions. Drug Metab Dispos 35:246-255. (Pubitemid 46148737)
12. Rostami-Hodjegan A and Tucker GT (2004) 'In silico' simulations to assess the 'in vivo' consequences of 'in vitro' metabolic drug-drug interactions. Drug Discov Today Tech 1:441-448. (Pubitemid 40186348)
13. Venkatakrishnan K and Obach RS (2007) Drug-drug interactions via mechanism-based cytochrome P450 inactivation: points to consider for risk assessment from in vitro data and clinical pharmacologic evaluation. Curr Drug Metab 8:449-462. (Pubitemid 47603409)
14. Wang YH (2010) Confidence assessment of the Simcyp time-based approach and a static mathematical model in predicting clinical drug-drug interactions for mechanism-based CYP3A inhibitors. Drug Metab Dispos 38:1094-1104.
15. Wang YH, Jones DR, and Hall SD (2004) Prediction of cytochrome P450 3A inhibition by verapamil enantiomers and their metabolites. Drug Metab Dispos 32:259-266. (Pubitemid 38176944)
16. Xu L, Chen Y, Pan Y, Skiles GL, and Shou M (2009) Prediction of human drug-drug interactions from time-dependent inactivation of CYP3A4 in primary hepatocytes using a population-based simulator. Drug Metab Dispos 37:2330-2339.
17. Yang J, Jamei M, Heydari A, Yeo KR, de la Torre R, Farré M, Tucker GT, and Rostami- Hodjegan A (2006) Implications of mechanism-based inhibition of CYP2D6 for the pharmacokinetics and toxicity of MDMA. J Psychopharmacol 20:842-849. (Pubitemid 44622750)
18. Yang J, Jamei M, Yeo KR, Tucker GT, and Rostami-Hodjegan A (2007) Prediction of intestinal first-pass drug metabolism. Curr Drug Metab 8:676-684. (Pubitemid 47578116)
19. Yang J, Liao M, Shou M, Jamei M, Yeo KR, Tucker GT, and Rostami-Hodjegan A (2008) Cytochrome p450 turnover: regulation of synthesis and degradation, methods for determining rates, and implications for the prediction of drug interactions. Curr Drug Metab 9:384-394.
20. Zhao P, Kunze KL, and Lee CA (2005) Evaluation of time-dependent inactivation of CYP3A in cryopreserved human hepatocytes. Drug Metab Dispos 33:853-861. (Pubitemid 40686640)
21. Zhao P, Zhang L, Grillo JA, Liu Q, Bullock JM, Moon YJ, Song P, Brar SS, Madabushi R, Wu TC, et al. (2011) Applications of physiologically based pharmacokinetic (PBPK) modeling and simulation during regulatory review. Clin Pharmacol Ther 89:259-267.